Litecoin just woke up—and it’s not playing small.
In a surprise twist that’s shaking up both Wall Street and Crypto Twitter, MEI Pharma (MEIP), a biotech company listed on Nasdaq, just announced plans to invest a massive $100 million into Litecoin (LTC). 📈
The news sent LTC soaring 10% in 24 hours, touching $111.40 on July 18. And that’s before they’ve even bought a single coin.
Why This Is Big 🧠💸
MEI isn’t just dipping toes—they’re going all in. They plan to raise $100M via a private stock sale and use 100% of it to buy LTC as their primary treasury reserve asset.
Even crazier?
👉 Charlie Lee, Litecoin’s creator, is joining MEI’s board.
👉 GSR, a major crypto trading firm, will manage their LTC stack.
👉 Backers include the Litecoin Foundation, ParaFi, CoinFund, and other big names.
What’s Fueling the Fire? 🔥
This move rides on two major waves:
1. GENIUS Act just passed the House—boosting blockchain innovation incentives.
2. CLARITY Act is expected soon—finally bringing regulatory clarity to crypto.
With these catalysts, Litecoin isn’t just moving—it’s positioning for a bigger breakout.
Final Thoughts 💬
This is the first-ever Nasdaq firm betting their treasury on LTC. If MEI's move succeeds, expect other companies to follow.
Is Litecoin about to have its MicroStrategy moment?
Stay sharp. Eyes on LTC.
---
Follow for more fast, real, no-BS crypto news. 🚀